α1-Antitrypsin Deficiency

Clin Chest Med. 2016 Sep;37(3):487-504. doi: 10.1016/j.ccm.2016.04.011. Epub 2016 Jun 25.

Abstract

α1-Antitrypsin deficiency is an autosomal codominant condition that predisposes to emphysema and cirrhosis. The condition is common but grossly under-recognized. Identifying patients' α1-antitrypsin deficiency has important management implications (ie, smoking cessation, genetic and occupational counseling, and specific treatment with the infusion of pooled human plasma α1-antitrypsin). The weight of evidence suggests that augmentation therapy slows the progression of emphysema in individuals with severe α1-antitrypsin deficiency.

Keywords: Augmentation therapy; Cirrhosis; Diagnostic testing; Emphysema; Targeted detection; α(1)-Antitrypsin deficiency.

Publication types

  • Review

MeSH terms

  • Disease Progression
  • Humans
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / genetics
  • Liver Cirrhosis / physiopathology*
  • Panniculitis / etiology
  • Panniculitis / genetics
  • Panniculitis / physiopathology
  • Pulmonary Emphysema / drug therapy
  • Pulmonary Emphysema / etiology
  • Pulmonary Emphysema / genetics
  • Pulmonary Emphysema / physiopathology*
  • Serine Proteinase Inhibitors / therapeutic use
  • Vasculitis / etiology
  • Vasculitis / genetics
  • Vasculitis / physiopathology
  • alpha 1-Antitrypsin / genetics*
  • alpha 1-Antitrypsin / therapeutic use
  • alpha 1-Antitrypsin Deficiency / complications
  • alpha 1-Antitrypsin Deficiency / drug therapy
  • alpha 1-Antitrypsin Deficiency / genetics
  • alpha 1-Antitrypsin Deficiency / physiopathology

Substances

  • Serine Proteinase Inhibitors
  • alpha 1-Antitrypsin